Trial Site Detail

 

Drug:
CB-839 + Talazoparib
Trial:
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Conditions: Solid Tumors
Trial Status:
Recruiting

 

UAB Comprehensive Cancer Center

1802 6th Ave. South     
Birmingham , AL 35294
USA

 

Principal Investigator:
Erica Stringer-Reasor, MD
Contact:
Likesar (Keisha) McCray 205-975-7265 lmccray@uab.edu
Activation Status of this Site:
Active
Notes about this Site:
UAB Comprehensive Cancer Center Website:
http://www3.ccc.uab.edu/patientresources/clinicaltrials.html

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.